Molenaar C, Teuben J M, Heetebrij R J, Tanke H J, Reedijk J
Department of Molecular Cell Biology, Leiden University Medical Centre, The Netherlands.
J Biol Inorg Chem. 2000 Oct;5(5):655-65. doi: 10.1007/s007750000153.
The cellular distribution and processing pathways of two platinum compounds, modeling the antitumor drug cisplatin (cDDP) in human osteosarcoma (U2-OS) cells is reported. A [Pt(en)Cl] entity has been covalently linked to a carboxyfluorescein diacetate (CFDA) moiety and to a dinitrophenyl (DNP) moiety. The two different constructs were administered to living cell cultures that were analyzed using digital fluorescence microscopy. The non-fluorescent CFDA construct becomes fluorescent after cellular uptake and subsequent acetate hydrolysis by esterases, and is therefore suitable to monitor platinum in living cells; the DNP construct can be visualized by immunocytochemistry and consequently serves as a control. Both complexes were readily internalized by the cells, and localized throughout the whole cell. After 2-3 h the complex accumulated in the nucleus, but 6-8 h after incubation a punctuate staining of a cytoplasmic region was observed, that persisted and became more pronounced after 24 h. The overall fluorescence in the cell decreased over time, implying a secretion of the platinum complex. Surprisingly, the accumulation remained visible after 72 h. Co-localization experiments with a Golgi apparatus-selective stain indicate the involvement of Golgi vesicles in intracellular processing of cisplatin-derived complexes. Immunocytochemical studies, using the DNP derivative, resulted in very similar images as obtained with the CFDA construct. CFDA-boc (a non-platinum-containing fluorescein derivative) was used as control: a faint staining throughout the whole cell was observed. Cisplatin-resistant U2-OS/Pt cells showed staining patterns very similar to the U2-OS cells using both platinum constructs. This study illustrates that only a very small portion of the platinum complex eventually remains bound to DNA, as after 24 h no significant fluorescence could be observed in the nucleus. Cisplatin-derived complexes with fluorescent tags afford a new insight into the cellular processing of these complexes and therefore may contribute to further unraveling of the mechanism of platinum antitumor complexes.
报道了两种铂化合物在人骨肉瘤(U2-OS)细胞中的细胞分布和加工途径,这两种铂化合物是抗肿瘤药物顺铂(cDDP)的模型。一个[Pt(en)Cl]实体已共价连接到一个羧基荧光素二乙酸酯(CFDA)部分和一个二硝基苯基(DNP)部分。将这两种不同的构建体施用于活细胞培养物,并使用数字荧光显微镜进行分析。非荧光CFDA构建体在细胞摄取并随后被酯酶水解乙酸酯后变为荧光,因此适合监测活细胞中的铂;DNP构建体可通过免疫细胞化学可视化,因此用作对照。两种复合物都很容易被细胞内化,并分布在整个细胞中。2-3小时后,复合物在细胞核中积累,但孵育6-8小时后,观察到细胞质区域有斑点状染色,这种染色持续存在并在24小时后变得更加明显。细胞中的总体荧光随时间下降,这意味着铂复合物的分泌。令人惊讶的是,72小时后积累仍可见。与高尔基体选择性染色的共定位实验表明高尔基体囊泡参与了顺铂衍生复合物的细胞内加工。使用DNP衍生物的免疫细胞化学研究产生了与CFDA构建体获得的非常相似的图像。CFDA-boc(一种不含铂的荧光素衍生物)用作对照:在整个细胞中观察到微弱的染色。顺铂耐药的U2-OS/Pt细胞使用两种铂构建体时显示出与U2-OS细胞非常相似的染色模式。这项研究表明,最终只有非常小一部分铂复合物与DNA结合,因为24小时后在细胞核中未观察到明显的荧光。带有荧光标签的顺铂衍生复合物为这些复合物的细胞加工提供了新的见解,因此可能有助于进一步阐明铂抗肿瘤复合物的作用机制。